首页> 中文期刊> 《中国药房》 >药源性横纹肌溶解症高危因素研究

药源性横纹肌溶解症高危因素研究

         

摘要

OBJECTIVE:To investigate and analyze the causative factors and characteristics of drug-induced rhabdomyolysis in China,in order to reduce the incidence of rhabdomyolysis. METHODS:Search all cases of rhabdomyolysis in China Knowledge Re-source Integrated Database from Jan 1975 to Jun 2014. Sex,age,disease history,drugs administered,drug combination,clinical presentation and outcome of rhabdomyolysis were censused and analyzed. RESULTS:There were altogether 185 rhabdomyolysis cas-es reported,of which 57.8% were over 60 years old ,78.9% were induced by lipid regulators,and 55.7% were by statins;74.1%occurred within 1 month after drug administration,and 86.6% became normal within 1 month when causative drugs discontinued or with treatment;and 4.9% died. CONCLUSIONS:Eldly,complicated with multi-factors,such as multiple organ dysfunction syn-drome,irrational drug combination and over-doses,especially with lipid regulators,are important causative factors of rhabdomyoly-sis. Individualized administration of drugs and prescription as less as possible should be recommended to reduce the incidence of rhabdomyolysis.%目的:研究药源性横纹肌溶解症(RM)发生的因素与规律,以期避免或减少药源性RM的发生。方法:检索、筛选中国期刊全文数据库(1975年1月-2014年6月)所有药物所致RM病例。对患者性别、年龄、疾病史、药物使用、联合用药情况和RM的临床表现、出现时间、转归进行统计、分析。结果:共检索到药源性RM185例,61岁及以上者占57.8%,78.9%由调脂药引起,其中他汀类占55.7%。74.1%于用药后1月内发生,86.6%的患者经停药及治疗后1个月内恢复正常,有4.9%死亡。结论:高龄、合并多脏器疾病、不合理的联合或超剂量用药均为致RM的高危因素。药物治疗应注重个体化,精简用药方案,以避免或减少RM的发生。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号